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Abstract
Background: Bartter Syndrome is a rare, genetically heterogeneous, mainly autosomal recessively inherited
condition characterized by hypochloremic hypokalemic metabolic alkalosis. Mutations in several genes encoding for
ion channels localizing to the renal tubules including SLC12A1, KCNJ1, BSND, CLCNKA, CLCNKB, MAGED2 and CASR
have been identified as underlying molecular cause. No genetically defined cases have been described in the
Iranian population to date. Like for other rare genetic disorders, implementation of Next Generation Sequencing
(NGS) technologies has greatly facilitated genetic diagnostics and counseling over the last years. In this study, we
describe the clinical, biochemical and genetic characteristics of patients from 15 Iranian families with a clinical
diagnosis of Bartter Syndrome.
Results: Age range of patients included in this study was 3 months to 6 years and all patients showed hypokalemic
metabolic alkalosis. 3 patients additionally displayed hypercalciuria, with evidence of nephrocalcinosis in one case.
Screening by Whole Exome Sequencing (WES) and long range PCR revealed that 12/17 patients (70%) had a
deletion of the entire CLCNKB gene that was previously identified as the most common cause of Bartter Syndrome
in other populations. 4/17 individuals (approximately 25% of cases) were found to suffer in fact from pseudo-Bartter
syndrome resulting from congenital chloride diarrhea due to a novel homozygous mutation in the SLC26A3 gene,
Pendred syndrome due to a known homozygous mutation in SLC26A4, Cystic Fibrosis (CF) due to a novel mutation
in CFTR and apparent mineralocorticoid excess syndrome due to a novel homozygous loss of function mutation in
HSD11B2 gene. 1 case (5%) remained unsolved.
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Conclusions: Our findings demonstrate deletion of CLCNKB is the most common cause of Bartter syndrome in
Iranian patients and we show that age of onset of clinical symptoms as well as clinical features amongst those
patients are variable. Further, using WES we were able to prove that nearly 1/4 patients in fact suffered from
Pseudo-Bartter Syndrome, reversing the initial clinical diagnosis with important impact on the subsequent
treatment and clinical follow up pathway. Finally, we propose an algorithm for clinical differential diagnosis of
Bartter Syndrome.
Keywords: Bartter syndrome, Whole exome sequencing, Pseudo-Bartter-syndrome
Background
Bartter Syndrome (BS), firstly reported by Bartter and
his colleagues in 1962, is a very rare autosomal recessive
salt-losing tubulopathy characterized by hypokalemic
metabolic alkalosis with normotensive hyperreninemia
and hyperaldosteronism [1] occurring with an estimated
incidence of 1.2/million in the population [2]. Based on
the loss of function mutations in the salt reabsorption
transporters and channels in the thick ascending limb of
the loop of Henle, genetically, five variants of this
syndrome have been described: type I resulting from loss
of function mutations in the Solute Carrier Family 12
Member 1 SLC12A1 gene encoding the apical
furosemide-sensitive Na-K-Cl co-transporter (OMIM
#600839), type II caused by mutations in the potassium
voltage-gated channel subfamily J member 1 (KCNJ1)
gene encoding the apical renal outer medullary potas-
sium channel (ROMK) (OMIM # 600359), type III
caused by mutations in the chloride voltage-gated chan-
nel Kb (CLCNKB) gene encoding the basolateral chloride
channel Kb (OMIM #602023), type IVa resulting from
dysfunction of the Barttin CLCNK type accessory beta
subunit (BSND) gene encoding Barttin, a subunit of
chloride-channels Ka and Kb (OMIM #606412) and fi-
nally, type IVb caused by co-mutation in the CLCNKA
and CLCNKB genes (OMIM #602024) [3–7]. Gitelman
syndrome which shares several clinical characteristics
with BS type III has been described later in history. In
contrast to BS type III, Gitelman syndrome is caused by
mutations in a single gene, SLC12A3 (OMIM #263800),
encoding the thiazide-sensitive sodium chloride
co-transporter (NCCT) in the distal convoluted tubule [8,
9]. More recently, 2 genes, namely calcium sensing recep-
tor (CASR) (OMIM #601198) and MAGE family member
D2 (MAGED2) (OMIM #300971, BS type V) have been
identified which cause autosomal dominant and X-linked
recessive forms of BS [10, 11].
Currently, from a phenotypical perspective, BS has
been classified into three different forms according to
the average age at onset of symptoms: antenatal BS, the
most severe form of BS, marked by polyhydramnios, hy-
percalciuria, nephrocalcinosis, hypochloremia and failure
to thrive in infancy; Second, classic BS which has a
milder phenotype and is usually diagnosed during late
adulthood. And third, Gitelman syndrome which com-
pared to other variants is marked with hypocalciuria and
hypomagnesaemia and is usually diagnosed during late
childhood and adulthood. In most cases, BS IVa and IVb
subtypes are accompanied by sensorineural deafness
[12]. However, the BS subtype can often not be deter-
mined clinically with certainty due to similar presenta-
tion of different forms, rendering diagnostics and precise
prognosis complex [13]. Despite the need for rigorous
classification of BS phenotypes, currently few practical
indicators exist.
Making the landscape of BS and BS-like clinical pre-
sentations appear even more complex, several renal and
extra-renal disorders as congenital chloride diarrhea,
Pendred syndrome, Cystic fibrosis as well as some ac-
quired conditions associated (for example laxative abuse)
may present clinically in a similar way as BS with
regards to hypokalemic metabolic alkalosis. However,
there is only a limited number of reports in the
literature investigating misdiagnosis of BS where in fact
other rare hypokalemic disorders (CF) were causative for
the phenotype [14–22]. Nevertheless, such clinical mis-
diagnosis can result in serious health problems due to
wrong treatment choices [23, 24]. However, novel high
throughput sequencing technologies nowadays offer an
additional diagnostic tool refining clinical diagnostics.
In the present study, we describe 17 patients from 15
Iranian families with a clinical diagnosis of BS. Imple-
menting WES as additional diagnostic step combined
with long-range PCR screening for CLCNKB, we identi-
fied the underlying genetic cause in 16/17 cases. While
we confirmed the clinical diagnosis of BS in 12 cases,
our genetic analysis established a diagnosis different
from BS in 4 cases. Additionally, we propose a
cost-efficient clinical differential diagnostic algorithm.
Results
Clinical and genetics findings are summarized in Table 1.
Laboratory results of all 17 patients showed severe hypo-
kalemic alkalosis. Comparison of normal ranges of urin-
ary calcium/creatinine ratio for age (hypercalciuria
screening) indicated that case 3 showed hypocalciuria
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and case 2, 8, and 10 showed hypercalciuria (age
dependent normal urinary creatinine/calcium ratios are
shown in Table S2). 9 out of 17 cases clinically presented
before age of 1 year, 2 out of 17 cases between 1 to 2
years old, 5 out of 17 cases between 2 to 3 years old and
one case at the age of 6 years. Case 9 and case 15 did
not survive due to severe hypokalemic metabolic alkal-
osis. In summary, we observed a spectrum of phenotypes
ranging from BS type I to Gitelman syndrome in these
families.
In order to investigate the underlying genetic causes,
we proceeded with WES analysis in patient 13 as an
index case. This revealed a deletion of the entire
CLCNKB gene (Fig. 1a). We therefore proceeded to
check the remaining 16 patients by Sanger sequencing
for this deletion. Due to high sequence similarity be-
tween CLCNKA and CLCNKB, we used long range PCR
generating a CLCNKB specific gene product by using
primer pairs with the forward primer in exon 9 and the
reverse primer in exon 14. This confirmed a homozy-
gous CLCNKB in 11 out of the remaining 16 cases as
well as the index case sent for WES initially. A total of
12 out of the 17 cases were found to carry the deletion
(Fig. 1b).
The remaining 5 samples not found to carry the
CLCNKB deletion were subsequently sent for WES. This
revealed a novel homozygous CFTR missense mutation
(NM_000492.3 (CFTR): c.473G > A, p. (Ser158Asn)) in
case 14. The mutated amino acid is highly conserved in 10
species down to zebrafish (Additional file 1: Figure S1)
and the variant minor allele frequency is extremely low in
control samples (0.00007381 in genomAD). Further, a
different variant at the same position, CFTR c.473G > C
has been previously reported in a case of Cystic fibrosis
[25]. The patient was a 27months old boy with a clinical
BS diagnosis living in the southeast of Iran where a hot
and dry weather pattern is prevalent. His medical records
revealed parental consanguinity and history of failure to
thrive, delayed growth, muscle weakness, dehydration and
polyuria. The diagnosis of BS had been established based
on the electrolytes disturbance (K+: 2.1 mEq/L), and blood
gas analysis (HCO3
−: 34mEq/L, PH: 7.58). Treatment
included KCl per 10mEq/day and he had not been
investigated for CF due to lack of significant respiratory
symptoms.
WES identified a novel homozygous canonical splice
site mutation at the exon /intron boundary of exon 8
of the SLC26A3 gene (NM000111.2; c.971 + 1G > T)
for case 15. Recessive loss of function mutations in
SLC26A3 have been previously reported to cause con-
genital chloride diarrhea [26]. This case was a 3
months old girl with a history of polyhydramnios,
failure to thrive, dehydration and polyuria. At the
time of birth, her body weight was 2.9 kg, height was
48 cm, and head circumference was 33 cm. After 3
months, she was hospitalized for delayed growth,
muscle weakness and significant electrolyte imbal-
ances. The diagnosis of BS had been established based
on the electrolyte disturbance (K+: 2, 6 mEq/L), blood
gas analysis (HCO3
−:47, PH: 7, 56) and she did not
have a noted history of diarrhea. The treatment in-
volved KCL ampoules (10 mEq/day) under which she
clinically improved.
For case 16, we detected a known homozygous missense
mutation in the SLC26A4 gene by WES (NM_000441.1
(SLC26A4): c.1226G > A, p. (Arg409His), and
rs111033305). This variant has been previously described
as pathogenic in ClinVar (RCV000169222.1). The variant
had previously been found in multiple Pendred patients,
however not associated with hypokalemic metabolic alkal-
osis [27–29]. Our case was an 18 months old boy de-
scending from consanguineous parents with a
prenatal history of severe polyhydramnios, fetal dis-
tress and meconium in the amniotic fluid. Postnatally,
failure to thrive with metabolic alkalosis, vomiting
and elevated body temperature were noted. Besides,
results of auditory brainstem response, the auditory
steady-state response, oto-acoustic emission and tym-
panometry tests showed bilateral mild hearing loss.
The diagnosis of BS had been established based on
the electrolytes disturbance (Cl−: 24 mEq/L, K+: 3
mEq/L), blood gas analysis (HCO3
−: 30.5, PH: 7.50)
and sensorial deafness. The stool exam showed no
OVA, cyst and amoeba. The treatment involved KCl
ampoules (10 mEq/day) and Spironolactone 25 mg
every 8 h.
Finally, WES revealed a novel homozygous loss of
function mutation in HSD11B2 (NM_000196
(HSD11B2): c.1120C > T, p.(Arg374*)), establishing the
genetic diagnosis of apparent mineralocordicoid excess
(AME). Our case was a 6 months old boy of consanguin-
eous parents. At the time of examination his body
weight was 5.50 kg with biography of failure to thrive,
hypokalemic metabolic alkalosis, and also small stones
in kidney sonography. Abdominal ultrasound did not re-
veal any abnormalities in the liver, pancreas, spleen and
bladder. His blood pressure values were in normal range
in the follow up exmaminations. The diagnosis of BS
was suggested based on blood electrolytes disturbance
(K+: 2.6 mEq/L) and blood gas analysis (HCO3
−: 31.2,
PH: 7.50).
Cases 5 remained unsolved.
Pedigrees of all 15 families are shown in Fig. 2, Normal
ranges of urinary calcium/creatinine ratio in children is
shown in Additional file 1: Figure S2, Sanger sequencing
primers can be found in Additional file 1: Figure S3,
sequencing results for family 12,13, 14 and 15 are shown
in Additional file 1: Figure S4.
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Fig. 1 (See legend on next page.)
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Discussion
In this Iranian cohort, deletion of the entire
CLCNKB gene was identified as the most common
allele causing BS. This is in line with previous find-
ings in other populations where this deletion has also
been found to represent the most common BS allele,
especially in BS type III. In our cohort, phenotypes
resulting from the deletion ranged from type I BS to
Gitelman syndrome. All individuals in our cohort
originated from the same region in the Southeast of
Iran (Baloch ethnicity). It is possible families are
remotely related and share a distant common ances-
tor. Interestingly, phenotypic presentations e.g. with
regards to the age at onset of the first symptoms and
presentations resembling different BS subtypes were
highly variable amongst individuals harboring the
identical CLCNKB deletion. Intrafamilial phenotypic
variability has been previously reported in a very
large inbred Bedouin kindred in Northern Israel as
well as a Spanish family [23, 30].
Putatively, the phenotypic differences observed could
be caused by non-genetic factors e.g. environmental in-
fluences or result from the different genetic background
between individuals (multigenic cause). Specifically,
genotypic differences with regards to other (chloride)
channels and transporters in the nephron resulting in
different expression levels or function could also play a
role (Fig. 3) [31, 32].
(See figure on previous page.)
Fig. 1 Visualization of CLCNKB deletion detected. (a) BAM files generated from WES data and displayed in IGV visualizing the deletion of the
entire CLCNKB gene in case 13 (bottom) while reads are present in case 16 (top) who carries a homozygous mutation in SLC26A4. (b)
Confirmation of CLCNKB deletion by long range PCR shown as absence of CLCNKB product in 12/16 patients on a 1% agarose gel containing
ethidium bromide. M =marker, Co = control
Fig. 2 Pedigrees of the 15 families included in this study and identified mutations. Affected individuals included in the study are numbered,
arrows indicate the index cases within the study
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To date, no larger studies have been published about
the incidence of clinical misdiagnosis of BS where in fact
other conditions are causative for the symptoms. Congeni-
tal chloride diarrhea results from loss of function
mutations in the SLC26A3 gene encoding an Cl−/HCO3
−
exchanger in the intestine (Fig. 3c). Previous to our report,
confounding congenital chloride diarrhea with BS has
been reported in 2 additional cases without mentioning
the underlying mutations [14, 15]. Potentially, watery diar-
rhea could be confounded with urine and with increasing
dehydration, the amount of diarrhea decreases, making a
diagnosis of congenital chloride diarrhea even more diffi-
cult. Unlike in BS patients where high urinary Cl− concen-
tration is found, low urinary and high fecal Cl− is detected
in congenital chloride diarrhea [33]. Thus, both congenital
chloride diarrhea and BS should be considered as differen-
tial diagnosis in patients with hypokalemic metabolic
alkalosis. Untreated congenital chloride diarrhea can be
lethal due to the acute and chronic dehydration and
secondary impairment of renal function. Although by KCl
or NaCl substitution electrolyte levels can be kept in
balance, this does not influence the amount of diarrhea.
Fig. 3 Schematic of localizations and function of ion transporters defective in Bartter Syndrome and Pseudo-Bartter conditions. ClC-kb is mainly
found in the thick ascending loop of Henle (TAL), (a) and distal tubules (DCT), (b) of kidneys, SLC26A3 in the intestine (c), Pendrin localizes mainly
to renal beta-intercalated cells (d), CFTR is found in all nephron segments (e), and 11β-HSD2 enzyme in cortical collecting duct (f). (a) Thick
ascending loop of Henle: Luminal NKCC2 enables import of Na+, K+ and Cl- into the cells. K+ flows back to the lumen through ROMK1 channels;
Na+ and Cl- are reabsorbed to the blood stream through Na+/K+ ATPase and ClC-kb channels. CASR inhibits the luminal ROMK channel which in
turn results in decreased NaCl reabsorption and increased urinary Cl-. (b) Distal Tubulus: Cl- transport occurs via the luminal, NCCT and exit to
blood by ClC-kb. (c) In enterocytes, Cl- absorbed from the intestinal lumen via SLC26A3 and transported to the interstitium by ClC-2. Na+ enters
the cell via ENaC channels or Na+/ H+ exchangers and is transported to the interstitium by the Na+/k+ ATPase. (d) Penderin participates in
urinary bicarbonate excretion with tubular Cl- reabsorption. (e) CFTR functions as a Cl- channel and CFTR functions influences other ion channels
such as ENaC and ROMK in the cortex and medulla. (f) mineralocorticoid aldosteron binds to Mineralcorticoid receptors (MR) which in turn binds
to the hormone response elements (HRE) in the nucleus and stimulates increased resorption of Na+ from the urine through transcription of
genes involved in ENac and Na+/K+ ATP channels. Simultaneously glucocorticoid cortisol oxidized to inactive cortisone by 11β-HSD2 enzyme
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Second clinical misdiagnosis of BS in our cohort
concerns a case which genetically turned out to repre-
sent Pendred syndrome. This syndrome is characterized
by severe to mild hearing loss and euthyroid goiter [34].
Diagnosis of BS in this 18 months old was made base on
hypokalemic metabolic alkalosis with sensorial deafness
without any sign of euthyroid goiter. As goiter manifest-
ation develops usually after the age of 10 years, Pendred
syndrome can easily misdiagnosed in infants as our case
[35]. Only a handful of patients with SLC26A4 muta-
tions and metabolic alkalosis have been reported in the
literature including a 46-year-old Caucasian female with
sensorineural deafness and hypothyroidism (Cl−: 86
mmol/l, K+:1.4 mmol/l, HCO3
−: 45 mmol/l), a child fol-
lowing thiazide therapy (potassium 1.7, chloride 70, so-
dium 129, HCO3 43.8, base excess + 17.8 mmol/l, pH
7.52), and another 46-year-old woman with sensori-
neural deafness, hypothyroidism, and profoundly low
potassium levels (K+:1.4 mmol/l, HCO3
−: 45 mmol/l) [16,
36, 37]. Pendred syndrome is caused by mutations in
SLC26A4 encoding Pendrin which acts as Cl−/HCO3
−
exchanger in the inner ear, thyroid and kidney [34].
Under basal conditions, Pendrin mediates acid- base bal-
ance through HCO3
− excretion and Cl− reabsorption in
the kidney in the β-intercalated cells of the cortical col-
lecting duct in the kidney (Fig. 3d) [38]. Loss of function
in the kidney is usually compensated by the other trans-
porters; therefore, malfunction of Pendrin in the kidney
does usually not result in detectable clinical symptoms.
However, it is suggested that Pendrin might have an
additional adaptive role in eliminating excess bicarbon-
ate in alkalosis conditions [16]. Pendred syndrome there-
fore should be considered in infants or very young
children with hypokalemic alkalosis and sensorial deaf-
ness alongside BS.
The third genetic revision of the initial clinical diagnosis
in our cohort concerns a case with homozygous CFTR
missense mutation manifesting as pseudo-BS. CFTR is a
chloride channel expressed in many organs, including the
kidneys. A number of publications have reported to date
that in regions with hot climate, patients younger than 2
years with CF may present electrolyte disturbance without
any other signs of respiratory and gastrointestinal abnor-
malities [39]. CFTR is expressed in all nephron segments
Fig. 4 Flow chart for diagnostic investigation of the Bartter syndrome, including genetic analysis. Antenatal Bartter syndrome (I & II) with
nephrocalcinosis, polyhydramnion, hypercalciuria and high prostaglandin level characteristics mostly caused by mutations in SLC12A1, KCNJ1
genes and in rare cases by mutations in CLCNKB, or in X-linked cases it caused by mutation in MAGED2 genes. During follow-up examintation of
these patients clinicians should also consider intestinal Cl− loss and watery diarrhea for differential diagnosis from congenital chloride diarrhea
which is caused by mutation in SLC26A3 gene. Classic Bartter syndrome (III) and Gitelman syndrome caused by mutation in CLCNKB and SLC12A3
genes, usually appeared in childhood but in rare cases they could also be present in infants. During follow-up examination of these patients
clinicians should also examine hypertension for differential diagnosis from Apparent mineralocorticoid excess which is caused by mutation in
HSD11B2 gene. And also they should scrutinize sweat chloride losses for differential diagnosis from cystic fibrosis. Type IV Bartter syndrome which
is accompany with sensorial deafness caused by BSND gene or digenic mutation in CLCNKA and CLCNKB genes. During follow-up examination
clinician should consider euthyroid goiter which usually have late onset manifestation for differential diagnosis from Pendred syndrome which is
caused by mutation in SLC26A4 gene. Finally type V Bartter which is caused by mutation in CASR gene characterized by mild or asymptomatic
hypocalcemia, low or normal serum parathyroid hormone, carpopedal spasm seizures and also it is associated with dominant phenotype of
Bartter syndrome
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where it is not only involved in Cl− transportation but also
regulates other ion channels such as ENaC and ROMK
through ATP transport (Fig. 3e) [40]. Several other patho-
genic CFTR variants such as 3849 + 40A >G, 2.789 + 5
G >A, F311 L, T3381, D110H, S13F, D110E, N1303K and
ΔF508 have been associated with hypokalemic metabolic
alkalosis [41]. To our knowledge, the c.473G >A mutation
has not been reported yet to manifest only with
pseudo-BS in the absence of respiratory and gastrointes-
tinal symptoms. However, in hot weather, like in southern
Iran, high sweat production rate lead to hypokalemia in
sweat and urine through massive NaCl loss and secondary
hyperaldosteronism Hypokalemic metabolic alkalosis is
observed in both BS and CF patients, but urinary chloride
loss in BS syndrome is higher than in CF patients.
In the fourth case with a clinical misdiagnosis of BS,
we identified ahomozygous HSD11B2 mutation, revers-
ing the diagnosis to AME. So far, fewer than 100 AME
cases have been reported in the literature. The clinical
hallmark of this disorder is hypokalemic metabolic alkal-
osis with severe childhood- or juvenile-onset hyporeni-
nemic hypertension [41]. Under normal conditions, the
mineralocorticoid aldosteron binds to mineralcorticoid
receptors (MR) which in turn bind to hormone response
elements (HRE) in the nucleus, resulting in transcription
of ENac and Na+/K+ ATP channels in renal collecting
duct cells. Simultaneously, the glucocorticoid cortisol
which has similar MR affinity as aldosterone is oxidized
to the inactive form cortisone by the 11β-HSD2 enzyme
(Fig. 3f ), inhibiting binding to MR. Under conditions of
impaired 11β-HSD2 function, cortisol which is present
in 1000–2000 times higher concentrations compared to
aldosterone, binds to MR, causing enhanced Na+ −re-
absorption which in turn leads to the expansion of intra-
vascular fluid, causing hypertension [42]. Diagnosis of
BS in the 6 month old patient described here was made
based on hypokalemic metabolic alkalosis with low birth
weight, failure to thrive and poor growth. Hypertension
however only occurs later during the course of AME,
thus does not help to differentiate AME from BS in tod-
dlers. [41, 43]. In addition, because the incidence of
hypertension is low in children less than three years of
age, routine blood pressure monitoring is not recom-
mended unless the patient is at risk for hypertension,
facilitating misdiagnosis of AME.
In summary, clinical misdiagnosis of BS in our cohort
was nearly 25%. This suggests a generally high chance
for BS misdiagnosis, especially in developing countries
where elaborated biochemical analysis is not available
due to considerable phenotypic overlap between differ-
ent rare hypokalemic disorders. Additionally, current
clinical classification of antenatal BS, classic BS and
Gitelman syndrome is complicated and not always spe-
cific. We found CLCNKB deletions to cause a broad
phenotypic spectrum. A clinical diagnostic algorithm is
proposed in Fig. 4 for patients with hypokalemic meta-
bolic alkalosis, low birth weight and failure to thrive
within the first 2 years of life. Common biochemical
markers related to different types of Bartter syndrome,
also watery diarrhea, hypertension, sweat chloride losses,
enlarged vestibular aqueducts (EVA) visible in CT-scans
and euthyroid goiter should be actively looked out for.
However, NGS approaches now allow time and cost
efficient parallel analysis of several (or all) coding genes,
offering additional diagnostic possibilities, independent
of correct clinical phenotype classification. In this study,
WES costs per sample were 250 USD including bioinfor-
matics (Novogene, Hongkong), not including variant
filtering performed in-house using the variant files
provided by the company. Wider implementation of
WES will hopefully result in more precise diagnosis and
targeted treatment approaches as well as new genetic
counseling opportunities, especially in countries with
limited biochemical testing facilities.
Conclusions
In summary, our data suggests that BS patients negative
for the common CLCNKB deletion profit from WES and
that Pseudo-BS e.g. due to CF, congenital chloride diar-
rhea, Pendred Syndrome and AME should be considered
as differential diagnosis in infants and young children
with hypokalemic metabolic alkalosis.
Methods
Human research subjects
Consent forms were obtained from all the participants
of this study. Ethical approval committee of Mashhad
University of medical sciences approved this study
(IR.MUMS.REC.1395.534). 17 patients from 15 families
referred to our clinics from 2016 to 2018 with diagnosis
of BS were included. The basic information and labora-
tory results of the patients have been summarized in
Table 1 and pedigrees have been shown in Fig. 1.
DNA extraction
Genomic DNA was extracted from whole blood, using
standard salting out method. The concentration of DNA
was measured by Qubit 2.0 (life technologies, Carlsbad,
CA, USA).
WES
2 microgram DNA from 6 patients out of 17 patients
[5, 13–17], and was used for WES, using Illumina
HiSeq 2500, Q30 ≥ 80% (Novogene, Hongkong). Ex-
ome capture was performed with Agilent SureSelect
Human All Exon V6 Kit, sequencing depth was 50×
using paired-end sequencing on a HiSeq 2500
Genome Analyzer (Illumina), resulting in sequences
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of 150 bases from each end of the fragments. UCSC
hg19 was used as a reference genome. VarScan ver-
sion 2.2.5 and MuTec and GATK Somatic Indel
Detector were used to detect SNV and InDels,
respectively. Data was filtered for MAF < 1% in public
control databases such as dbSNP, ExAc and gnomad
(gnomAD, http://gnomad.broadinstitute.org). Addition-
ally, variants occurring with MAF > 0.01 in the Iranome
(http://www.iranome.ir) were also excluded. The remaining
variants were filtered for known disease causing genes first
and we prioritized homozygous variants due to the auto-
somal recessive inheritance pattern of disease and consan-
guinity. For families without plausible variants left after
filtering, BAM files were visually inspected for homozy-
gous CNVs in known disease causing genes related to a
hypokalemic metabolic phenotype.
PCR and sanger sequencing
Conventional PCR was done by Taq polymerase (Roche,
Mannheim, Germany) based on manufacture’s instruc-
tion to extend the mutated region with specific primer.
Also, long range PCR (200 bp-4 kb) was done by Accu-
Prime™ Taq DNA polymerase system to confirm deletion
in CLCNKB gene with specific primer according to the
following condition, 2.5 μl of 10x AccuPrime™ PCR
Buffer II, 0.5 μl of Primer Mix (10 μM each), 1-200 ng of
template DNA, 0.5 μl of AccuPrime™ Taq DNA polymer-
ase in total of 25 autoclaved distilled water (initial
denaturation at 94 °C for 2 min; followed by 40 cycles of
denaturing at 94 °C for 30s, annealing at 65 °C for 30s,
and extension at 68 °C for 3 min and final extension at
68 °C for 5 min). Primer sequences are in Table S1. Be-
fore Sanger sequencing, PCR products were cleaned by
ExoSAP-IT® (USB, Cleveland, Ohio, USA). The cleanup
PCR products were bidirectional sequenced using
3730XL DNA analyzer (ABI, Foster City).
Web resources
Homozygosity-Mapper, http://www.homozygositymap-
per.org/.
Exome Aggregation Consortium (ExAC), http://exac.-
broadinstitute.org/.
Genome Aggregation Database (gnomAD), http://gno-
mad.broadinstitute.org/.
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/.
1000 Genomes Project human polymorphism database,
http://www.1000genomes.org/.
National Heart, Lung and Blood Institute–Exome
Sequencing Project, http://evs.gs.washington.edu/EVS/.
Online Mendelian Inheritance in Man, http://www.
omim.org/.
Integrated genome viewer (IGV), http://software.broad
institute.org/software/igv/.
Additional file
Additional file 1: Figure S1. Aminoacid conservation of CFTR
p.Ser158Asn. Figure S2. Normal ranges of urinary calcium/creatinine ratio
in children. Figure S3. Sanger sequencing primers used. Figure S4.
Sanger traces of identified mutations in non-Bartter-Syndrome genes.
(DOCX 648 kb)
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